Tonix Pharmaceuticals Holding Corp (TNXP)
0.1378
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 12:21
Tonix Pharmaceuticals Research and Development Expense (Quarterly): 9.698M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 9.698M |
| March 31, 2024 | 12.86M |
| December 31, 2023 | 17.12M |
| September 30, 2023 | 21.05M |
| June 30, 2023 | 21.98M |
| March 31, 2023 | 26.51M |
| December 31, 2022 | 24.67M |
| September 30, 2022 | 22.20M |
| June 30, 2022 | 16.58M |
| March 31, 2022 | 18.42M |
| December 31, 2021 | 22.30M |
| September 30, 2021 | 13.08M |
| June 30, 2021 | 18.13M |
| March 31, 2021 | 15.33M |
| December 31, 2020 | 12.10M |
| September 30, 2020 | 8.813M |
| June 30, 2020 | 10.57M |
| March 31, 2020 | 4.676M |
| December 31, 2019 | 5.69M |
| September 30, 2019 | 5.052M |
| June 30, 2019 | 3.554M |
| March 31, 2019 | 3.896M |
| December 31, 2018 | 5.057M |
| September 30, 2018 | 3.264M |
| June 30, 2018 | 4.067M |
| Date | Value |
|---|---|
| March 31, 2018 | 5.17M |
| December 31, 2017 | 3.634M |
| September 30, 2017 | 3.908M |
| June 30, 2017 | 2.806M |
| March 31, 2017 | 2.994M |
| December 31, 2016 | 4.88M |
| September 30, 2016 | 5.466M |
| June 30, 2016 | 7.516M |
| March 31, 2016 | 10.67M |
| December 31, 2015 | 9.49M |
| September 30, 2015 | 10.31M |
| June 30, 2015 | 8.871M |
| March 31, 2015 | 6.829M |
| December 31, 2014 | 5.775M |
| September 30, 2014 | 5.217M |
| June 30, 2014 | 4.075M |
| March 31, 2014 | 3.55M |
| December 31, 2013 | 1.328M |
| September 30, 2013 | 1.637M |
| June 30, 2013 | 0.944M |
| March 31, 2013 | 0.741M |
| December 31, 2012 | 0.7004M |
| September 30, 2012 | 0.6581M |
| June 30, 2012 | 0.8278M |
| March 31, 2012 | 0.3976M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.676M
Minimum
Mar 2020
26.51M
Maximum
Mar 2023
15.88M
Average
16.58M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Emergent BioSolutions Inc | 32.70M |
| Geovax Labs Inc | 4.277M |
| Abbott Laboratories | 713.00M |
| SIGA Technologies Inc | -- |
| Chimerix Inc | 18.43M |